Towards Healthcare

Membranes for Pharmaceuticals and Biotechnology Companies, Market Entry and Expansion Strategies

Date : 27 March 2026

Top Vendors in the Membranes for Pharmaceuticals and Biotechnology Market & Their Offerings

Membranes for Pharmaceuticals and Biotechnology Companies are Danaher Corporation, Sartorius AG, 3M Company, Merck KGaA, Asahi Kasei Corporation

Companies Headquarters Offerings
Danaher Corporation Washington, D.C., USA Filtration and purification membranes via Cytiva & Pall for bioprocessing, viral filtration, and protein separation.
Sartorius AG Göttingen, Germany Membrane filters for sterile filtration, ultrafiltration, and single-use bioprocessing systems
3M Company Minnesota, USA Advanced membrane filters for sterilization, drug filtration, and purification processes. 
Merck KGaA  Darmstadt, Germany Millipore membrane technologies for filtration, viral clearance, and bioprocessing applications
Asahi Kasei Corporation Tokyo, Japan Hollow fiber membranes for virus removal, plasma fractionation, and biopharma processing
Hangzhou Cobetter Filtration Equipment Co., Ltd.  Hangzhou, China  Membrane cartridges and filtration systems for sterile filtration and biologics production
Repligen Corporation Massachusetts, USA Hollow fiber membranes and filtration systems for protein purification and downstream processing

Supply Chain Analysis

R&D:

  • R&D in membranes for pharmaceutical and biotechnology applications is mainly focused on enhancing purification efficiency, improving productivity, and supporting advanced therapeutic processes. The goal is to achieve high-performance, cost-effective bioprocessing solutions to meet rising industry demand. Continuous innovation in membrane materials and design is enabling better separation and scalability.
  • Key players: Merck KGaA, Danaher Corporation, Sartorius AG, 3M Company, and Pall Corporation.

Clinical Trials:

  • Clinical research on membranes in pharmaceutical and biotechnology applications mainly focuses on three key areas: regenerative medicine and tissue engineering using biomaterial-based membranes, advanced drug delivery through implantable membrane systems, and efficient bioprocessing using microfiltration and ultrafiltration techniques. These studies aim to improve therapeutic outcomes and process efficiency.
  • Key players: Thermo Fisher Scientific, GE HealthCare, Asahi Kasei Corporation, Koch Separation Solutions, and Repligen Corporation.

Formulation and Final Dosage Preparation:

  • Membrane formulation for pharmaceutical and biotechnology use involves careful selection of polymers, solvents, and additives to achieve the desired pore size, permeability, and biocompatibility. These membranes play a crucial role in drug delivery, sterilization, protein purification, and tissue engineering. Common fabrication methods include phase inversion, interfacial polymerization, and electrospinning, ensuring precise and efficient performance.
  • Key players: Ecolab Inc., Arkema, Toray Industries, DuPont, and Snyder Filtration

The Biopharmaceutical Companies Segment held the Largest Market Share in 2025.

Segment Share 2025 (%)
Biopharmaceutical Companies 40%
Contract Research/Manufacturing Organizations 25%
Pharmaceutical Companies 20%
Academic & Research Institutes 15%

Explanation

  • Biopharmaceutical Companies led with 40%, driven by the growing demand for innovative therapies and biologics in the healthcare sector.
  • Contract Research/Manufacturing Organizations accounted for 25%, supported by their role in providing specialized services for drug development and manufacturing.
  • Pharmaceutical Companies held 20%, benefiting from the strong and steady demand for traditional pharmaceutical products and treatments.
  • Academic & Research Institutes represented 15%, with their increasing involvement in drug discovery and medical research, though they remain smaller than the other end-users.

The biopharmaceutical companies segment held the largest membranes for pharmaceuticals and biotechnology market share by 40% in 2025 due to the high production of biologics, biosimilars, and purification. These companies rely heavily on membranes for efficient downstream processing, ensuring product quality and regulatory compliance. Strong investments in R&D, large-scale manufacturing capabilities, and increasing demand for complex biologic drugs further drive dominance, making them the primary end users in the pharmaceutical and biotechnology membrane market.

The contract research/manufacturing organizations segment is expected to grow at the fastest CAGR due to increasing outsourcing of drug development and manufacturing by biopharmaceutical companies. These organizations offer cost-effective, flexible, and scalable solutions, driving higher adoption of membrane technologies for filtration and purification. Rising demand for biologics, faster time-to-market, and reduced infrastructure investment are further accelerating their growth in the pharmaceutical and biotechnology market.

Market Growth

The global membranes for pharmaceuticals and biotechnology market size was estimated at USD 5.13 billion in 2025 and is predicted to increase from USD 5.49 billion in 2026 to approximately USD 10.15 billion by 2035, expanding at a CAGR of 7.06% from 2026 to 2035.

Membranes for Pharmaceuticals and Biotechnology Size is USD 5.49 Billion in 2026.

What are the Recent Developments in the membranes for Pharmaceuticals and Biotechnology Market?

  • In March 2026, the Asahi Kasei Corporation continued innovation in hollow fiber membranes to improve virus removal and separation efficiency in biopharmaceutical applications.
  • In February 2026, the Repligen Corporation expanded its filtration product line, focusing on high-performance membranes for protein purification and biologics processing.
  • In March 2025, Sartorius AG introduced improved membrane solutions aimed at increasing process efficiency and reducing filtration time in downstream applications.